Gilotrif Side Effects
Generic Name: afatinib
Note: This page contains information about the side effects of afatinib. Some of the dosage forms included on this document may not apply to the brand name Gilotrif.
Not all side effects for Gilotrif may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to afatinib: oral tablet
In addition to its needed effects, some unwanted effects may be caused by afatinib (the active ingredient contained in Gilotrif). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking afatinib:More common
- Bloody or cloudy urine
- burning, dry, or itching eyes
- difficult, burning, or painful urination
- discharge or excessive tearing
- frequent urge to urinate
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- redness, swelling, or pain of the skin
- scaling of the skin on the hands and feet
- tingling of the hands and feet
- ulceration of the skin
- difficult breathing
- shortness of breath
If any of the following symptoms of overdose occur while taking afatinib, get emergency help immediately:Symptoms of overdose
- Abdominal or stomach pain
- lack or loss of strength
Some of the side effects that can occur with afatinib may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Blemishes on the skin
- canker sores
- chapped, red, or swollen lips
- decreased appetite
- decreased weight
- dry skin
- itching skin
- loosening of the fingernails
- redness or soreness around the fingernails
- runny nose
- scaling, redness, burning, pain, or other signs of inflammation of the lips
- sores, ulcers, or white spots on the lips or tongue or inside the mouth
For Healthcare Professionals
Applies to afatinib: oral tablet
The most frequent serious adverse reactions reported were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each). Fatal adverse reactions included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%).
Dose reductions due to adverse reactions were required in 57% of patients. The most frequent adverse reactions that led to dose reduction were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).
Discontinuation of therapy for adverse reactions was 14.0%. The most frequent adverse reactions that led to discontinuation were diarrhea (1.3%), ILD (0.9%), and paronychia (0.9%).[Ref]
Very common (10% or more): Diarrhea (96%), stomatitis (71%), cheilitis (12%)[Ref]
Very common (10% or more): Acneiform rash/dermatitis (90%), paronychia (58%), dry skin (31%), pruritus (21%)[Ref]
Very common (10% or more): Cystitis (13%)[Ref]
Very common (10% or more): Alanine aminotransferase increased (11%)
Common (1% to 10%): Aspartate aminotransferase increased (8%)[Ref]
Very common (10% or more): Decreased appetite (29%), weight decreased (17%)[Ref]
Very common (10% or more): Conjunctivitis (11%)[Ref]
Very common (10% or more): Pyrexia (12%)[Ref]
Very common (10% or more): Epistaxis (17%), rhinorrhea (11%)[Ref]
1. "Product Information. Gilotrif (afatinib)." Boehringer Ingelheim, Ridgefield, CT.
More about Gilotrif (afatinib)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.